Skip to main content
OpenTrials
Completed

NCT Number: NCT02571959

Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults

Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy voluntary obese after oral and intra venous administration Determination of the pharmacokinetic parameters of amoxicillin / clavulanic acid obtained from plasmatic concentrations of intravenous injection (IV) and oral administrations. The criterion of evaluation allowing to answer our main objective corresponds to the parameters estimated by the pharmacokinetic model of the concentrations obtained from the data IV and by the pharmacokinetic model of the concentrations obtained from the oral data. The following pharmacokinetic parameters will be considered at every obese volunteer's for both molecules (amoxicillin and clavulanic acid) from the concentrations by pharmacokinetic analysis of population.

The main evaluation criteria are PK parameters of amoxicillin / clavulanic:

* Cl, systematic plasmatic clearance * Vd, volume of distribution * ASC 0-oo, area under the curve time - concentration * T1/2, half-life time * F, bioavailability after oral administration * Ka, constant of speed of absorption

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Hopital Ambroise Pare

Boulogne, 92100, France

About this study

Main objective Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy voluntary obese after oral and intra venous administration

Secondary objectives

  • Define dosage plans optimized with the antibiotic treatment to the obese subject
  • Ensure an adequacy of the treatment with the related infection
  • Formulate recommendations of dosage adaptations for a better individualization of treatments, by estimating several plans of doses by simulation to reach various PK/PD goals according to different theoretical MIC

Methodology

The pharmacokinetic analysis will be realized by approach of population allowing the estimation of the average parameters of amoxicillin and clavulanic acid as well as the interpersonal variability after an administration IV and an oral administration. Parameters's population and their variability will be estimated with the SAEM algorithm implemented in the software Monolix ( www.lixoft.eu ).

For the main objective, PK parameters PK of amoxicillin and clavulanic acid will be determined to day 1 and day 2. They will be described by means of indicators of position (average and median) and of dispersal (standard deviations, quartiles).

For secondary objectives, the profiles concentration/time of 1000 obese subjects will be determined by Monte Carlo method from PK parameters estimated at the balance by the model. For every feigned profile, the time during which the plasmatic concentration of amoxicillin and clavulanic acid is superior to a panel of theoretical MIC will be calculated by means of curves concentration - time determined for each of the subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary obese
  • Body mass index upper to 30 kg/m2
  • Age from 18 to 65 years
  • Signed free and lit consent
  • Possible participation according to the national file of the volunteers of the French Ministry of Health.
  • Volunteers affiliated to the Social Security

Exclusion criteria

  • Pregnancy
  • Evolutionary pregnancy or feeding
  • Allergy in ß-lactamines (nettle rash, oedema of Quincke)
  • Digestive intolerance with amoxicillin / clavulanic acid
  • Infection by the virus of the HIV ( positive Ac anti HIV)
  • Infection by the virus of the hepatitis B ( positive Ag Hbs)
  • Infection by the virus of the hepatitis C ( positive Ac anti VHC)
  • Hepatic cirrhosis at the Child-Pugh C stage(stadium)
  • Biological parameters:
  • Polynucléaires neutrophiles 750 / mm3
  • Haemoglobin 8g / dL
  • Patellets 60 000 / mm3
  • Creatinin clearance, according to MDRD, DFG 50 mL / min / 1,73m2
  • ASAT or ALAT > 3 times the superior limit of the normal (LSN)
  • Phosphatase alkaline > 3 LSN
  • Total Bilirubine > 3 LSN
  • Lipase > 3 LSN
  • Factor V < 50 %
  • Alcoholism chronicles (consumption superior to 30 g of alcohol a day, amount to 3 glasses of wine)
  • Significant anomaly of the electrocardiogram, in particular QTc > 450 msec
  • Subject susceptible not to respect the modalities of the study
  • Drug addiction intra venous
  • Any medical conditions which according to the judgment(sentence) of the investigator would may interfere with the moderate pharmacokinetic parameters
  • People placed under legal protection
  • Histories of bariatric surgery

Treatment and study plan

Amoxicillin and Clavulanic Acid

Drug

Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered

Other names: AMOXICILLINE / acide clavulonique SANDOZ

Primary outcomes

  1. Systematic plasmatic clearance (Cl)

    Time frame: 1 day

Secondary outcomes

  1. Area under the curve time - concentration (AUC 0-oo)

    Time frame: 1 day

  2. Half-life time (T1/2)

    Time frame: 1 day

  3. Volume of distribution (Vd)

    Time frame: 1 day

  4. Bioavailability after oral administration (F)

    Time frame: 1 day

  5. Constant of speed of absorption (Ka)

    Time frame: 1 day

Sponsors and collaborators

Lead sponsor

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Other

Registry information

Official study title

Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO)

Acronym: PHACO

Important dates

Study start
2015
Primary completion
2015
Study completion
2017
First posted
Oct 8, 2015
Registry last updated
Jan 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.